Introduction
Among the growing family of mitochondrial-derived peptides (MDPs), MOTS-c occupies a unique position as the first shown to regulate systemic metabolism. Discovered in 2015, this 16-amino acid peptide encoded within the mitochondrial genome has attracted significant research interest for its roles in glucose metabolism, exercise physiology, and aging — earning it the informal designation of an “exercise mimetic” in published literature.
This guide examines published research on MOTS-c for educational purposes only. It does not constitute medical advice. All products referenced are intended for laboratory research use.
What Is MOTS-c?
MOTS-c (Mitochondrial Open Reading Frame of the Twelve S rRNA type-c) is a 16-amino acid peptide with the sequence MRWQEMGYIFYPRKLR. Its molecular weight is approximately 2,174 Da.
Unlike the vast majority of known bioactive peptides, which are encoded in nuclear DNA, MOTS-c is encoded within the 12S ribosomal RNA gene of mitochondrial DNA (mtDNA). This makes it part of a small but growing class of mitochondrial-derived peptides that includes humanin and the SHLP family (SHLP1-6).
MOTS-c was identified by the laboratory of Dr. Pinchas Cohen at the University of Southern California (USC) Leonard Davis School of Gerontology, with the discovery published in Cell Metabolism in March 2015.
Mechanism of Action
AMPK Activation
Research suggests that MOTS-c’s primary mechanism involves activation of AMP-activated protein kinase (AMPK), the cell’s master metabolic regulator. AMPK activation promotes glucose uptake, fatty acid oxidation, and mitochondrial biogenesis while suppressing energy-consuming anabolic processes.
Folate-Methionine Cycle Regulation
Studies indicate that MOTS-c regulates the folate cycle and de novo purine biosynthesis pathway. By inhibiting the folate cycle, MOTS-c leads to accumulation of the intermediate AICAR (5-aminoimidazole-4-carboxamide ribonucleotide), which is itself a potent AMPK activator. This creates a metabolic cascade linking one-carbon metabolism to energy sensing.
Nuclear Translocation
A notable finding from the Cohen laboratory is that MOTS-c translocates from mitochondria to the cell nucleus under metabolic stress conditions. Once in the nucleus, it interacts with nuclear DNA to regulate gene expression related to the antioxidant response element (ARE) and NFE2L2 pathway — effectively providing a communication channel between mitochondria and the nuclear genome.
Exercise Mimetic Properties
Published research has characterized MOTS-c as an “exercise mimetic” due to its ability to activate many of the same metabolic pathways triggered by physical exercise, including AMPK signaling, improved glucose disposal, and enhanced mitochondrial function.
Key Research Findings
1. Original Discovery — Metabolic Regulation (2015)
Lee et al. demonstrated that MOTS-c treatment in mice prevented age-dependent and high-fat-diet-induced insulin resistance, reduced obesity, and improved overall metabolic homeostasis. The peptide enhanced glucose clearance and skeletal muscle glucose uptake through AMPK-dependent mechanisms.
Citation: Lee C, Zeng J, Drew BG, et al. “The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance.” Cell Metabolism. 2015;21(3):443-454. DOI: 10.1016/j.cmet.2015.02.009
2. Exercise and Physical Performance (2021)
Reynolds et al. published in Nature Communications showing that MOTS-c levels increase in skeletal muscle and plasma following exercise in both mice and humans. Exogenous MOTS-c administration improved physical performance in young mice, middle-aged mice, and aged mice. Notably, the peptide enhanced exercise capacity even in older animals, suggesting age-independent effects.
Citation: Reynolds JC, Lai RW, Woodhead JST, et al. “MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis.” Nature Communications. 2021;12:470. DOI: 10.1038/s41467-020-20790-0
3. Insulin Sensitivity in Aging (2018)
Kim et al. found that circulating MOTS-c levels decline with age in both mice and humans. Administration of MOTS-c to aged mice improved insulin sensitivity and metabolic function, suggesting that declining MOTS-c may contribute to age-related metabolic dysfunction.
Citation: Kim SJ, Miller B, Mehta HH, et al. “The mitochondrial-derived peptide MOTS-c is a regulator of plasma metabolites and enhances insulin sensitivity.” Physiological Reports. 2019;7(13):e14171.
4. Human Longevity Variants (2021)
Zempo et al. identified specific mitochondrial DNA variants in the MOTS-c-encoding region (m.1382A>C) that are associated with exceptional longevity in Japanese centenarians. The variant produces a functionally distinct MOTS-c (K14Q substitution), suggesting that MOTS-c biology may contribute to human lifespan variation.
Citation: Zempo H, Kim SJ, Fuku N, et al. “A pro-diabetogenic mtDNA polymorphism in the mitochondrial-derived peptide, MOTS-c.” Aging. 2021;13(2):1692-1717.
5. Stress Response and Nuclear Translocation (2019)
Kim et al. demonstrated that MOTS-c translocates to the nucleus during metabolic stress, where it regulates adaptive nuclear gene expression. This finding established MOTS-c as a mitochondrial signal that directly modulates nuclear transcription — a form of retrograde signaling from mitochondria to nucleus.
Citation: Kim SJ, Mehta HH, Wan J, et al. “Mitochondrial peptides modulate mitochondrial function during cellular senescence.” Aging. 2018;10(6):1239-1256.
Aging and Longevity Context
MOTS-c sits at the intersection of several hallmarks of aging: mitochondrial dysfunction, deregulated nutrient sensing, and altered intercellular communication. Research suggests that declining MOTS-c levels with age may contribute to metabolic deterioration, and that restoring MOTS-c signaling could address multiple aging pathways simultaneously.
The identification of longevity-associated MOTS-c variants in centenarian populations provides epidemiological evidence supporting the peptide’s role in healthy aging, though the mechanisms connecting specific variants to lifespan extension remain under active investigation.
Safety Profile
Published preclinical studies have not reported significant adverse effects from MOTS-c administration in animal models. However, it is important to note that human clinical trial data for MOTS-c is extremely limited. Most safety data comes from rodent studies with relatively short observation periods.
As with any research compound, the long-term safety profile remains to be established through properly controlled human studies. Researchers should exercise appropriate caution and follow institutional safety protocols when working with MOTS-c.
Frequently Asked Questions
What makes MOTS-c different from other peptides?
MOTS-c is one of very few known bioactive peptides encoded in mitochondrial DNA rather than nuclear DNA. This gives it a unique role as a mitochondrial-to-nuclear signaling molecule.
Why is MOTS-c called an “exercise mimetic”?
Research published in Nature Communications demonstrated that MOTS-c activates many of the same metabolic pathways as physical exercise, including AMPK signaling and improved glucose metabolism. Its levels also increase naturally during exercise.
Do MOTS-c levels change with age?
Studies indicate that circulating MOTS-c levels decline with age in both mice and humans, which may contribute to age-related metabolic dysfunction.
Has MOTS-c been tested in humans?
While MOTS-c levels have been measured in human blood and tissue samples, and genetic variants have been studied in human populations, controlled clinical trials of exogenous MOTS-c administration in humans remain limited.
How is MOTS-c typically administered in research settings?
In published animal studies, MOTS-c has been administered via intraperitoneal injection. Standard research protocols typically involve reconstitution from lyophilized powder in bacteriostatic water.
What is the relationship between MOTS-c and humanin?
Both are mitochondrial-derived peptides (MDPs) encoded in mitochondrial DNA. Humanin was discovered first (2001) in the 16S rRNA gene, while MOTS-c was identified in 2015 in the 12S rRNA gene. They activate different signaling pathways but both are involved in metabolic regulation and cellular stress responses.
References
- Lee C, et al. “The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance.” Cell Metabolism. 2015;21(3):443-454. DOI: 10.1016/j.cmet.2015.02.009
- Reynolds JC, et al. “MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis.” Nature Communications. 2021;12:470. DOI: 10.1038/s41467-020-20790-0
- Kim SJ, et al. “The mitochondrial-derived peptide MOTS-c is a regulator of plasma metabolites and enhances insulin sensitivity.” Physiological Reports. 2019;7(13):e14171.
- Zempo H, et al. “A pro-diabetogenic mtDNA polymorphism in the mitochondrial-derived peptide, MOTS-c.” Aging. 2021;13(2):1692-1717.
- Kim SJ, et al. “Mitochondrial peptides modulate mitochondrial function during cellular senescence.” Aging. 2018;10(6):1239-1256.
Disclaimer: This content is for educational and research purposes only. CertaPeptides supplies research-grade peptides for laboratory use. This is not medical advice. Consult a healthcare professional for any health-related decisions.